CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients by Schulz, Uwe et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic
Transplant Recipients
Schulz, Uwe; Solidoro, Paolo; Müller, Veronika; Szabo, Attila; Gottlieb, Jens; Wilkens, Heinrike;
Enseleit, Frank
Abstract: Intravenous ganciclovir and, increasingly, oral valganciclovir are now considered the mainstay
of treatment for cytomegalovirus (CMV) infection or CMV disease. Under certain circumstances, CMV
immunoglobulin (CMVIG) may be an appropriate addition or, indeed, alternative. Data on monotherapy
with CMVIG are limited, but encouraging, for example in cases of ganciclovir intolerance. In cases of
recurrent CMV in thoracic transplant patients after a disease- and drug-free period, adjunctive CMVIG
can be considered in patients with hypogammaglobulinemia. Antiviral-resistant CMV, which is more
common among thoracic organ recipients than in other types of transplant, can be an indication for in-
troduction of CMVIG, particularly in view of the toxicity associated with other options, such as foscarnet.
Due to a lack of controlled trials, decision-making is based on clinical experience. In the absence of a
robust evidence base, it seems reasonable to consider the use of CMVIG to treat CMV in adult or pedi-
atric thoracic transplant patients with ganciclovir-resistant infection, or in serious or complicated cases.
The latter can potentially include (i) treatment of severe clinical manifestations, such as pneumonitis or
eye complications; (ii) patients with a positive biopsy in end organs, such as the lung or stomach; (iii)
symptomatic cases with rising polymerase chain reaction values (for example, higher than 5.0 log10) de-
spite antiviral treatment; (iv) CMV disease or CMV infection or risk factors, such as CMV-IgG-negative
serostatus; (vi) ganciclovir intolerance; (vii) patients with hypogammaglobulinemia.
DOI: https://doi.org/10.1097/TP.0000000000001097
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-134344
Published Version
Originally published at:
Schulz, Uwe; Solidoro, Paolo; Müller, Veronika; Szabo, Attila; Gottlieb, Jens; Wilkens, Heinrike; Enseleit,
Frank (2016). CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant
Recipients. Transplantation, 100 Supp:S5-S10.
DOI: https://doi.org/10.1097/TP.0000000000001097
CMV Immunoglobulins for the Treatment of CMV
Infections in Thoracic Transplant Recipients
Uwe Schulz, MD,1 Paolo Solidoro, MD,2 Veronika Müller, MD, PhD,3 Attila Szabo, MD, DSc,4 Jens Gottlieb, MD,5
Heinrike Wilkens, MD,6 and Frank Enseleit, MD7
Abstract: Intravenous ganciclovir and, increasingly, oral valganciclovir are now considered the mainstay of treatment for cyto-
megalovirus (CMV) infection or CMV disease. Under certain circumstances, CMV immunoglobulin (CMVIG) may be an appropriate
addition or, indeed, alternative. Data onmonotherapy with CMVIG are limited, but encouraging, for example in cases of ganciclovir
intolerance. In cases of recurrent CMV in thoracic transplant patients after a disease- and drug-free period, adjunctive CMVIG can
be considered in patients with hypogammaglobulinemia. Antiviral-resistant CMV, which is more common among thoracic organ
recipients than in other types of transplant, can be an indication for introduction of CMVIG, particularly in view of the toxicity asso-
ciated with other options, such as foscarnet. Due to a lack of controlled trials, decision-making is based on clinical experience. In
the absence of a robust evidence base, it seems reasonable to consider the use of CMVIG to treat CMV in adult or pediatric tho-
racic transplant patients with ganciclovir-resistant infection, or in serious or complicated cases. The latter can potentially include
(i) treatment of severe clinical manifestations, such as pneumonitis or eye complications; (ii) patients with a positive biopsy in
end organs, such as the lung or stomach; (iii) symptomatic cases with rising polymerase chain reaction values (for example, higher
than 5.0 log10) despite antiviral treatment; (iv) CMV disease or CMV infection or risk factors, such as CMV-IgG–negative serostatus;
(vi) ganciclovir intolerance; (vii) patients with hypogammaglobulinemia.
(Transplantation 2016;100: S5–S10)
Treatment Strategies for CMV Events After Thoracic
Transplantation
The incidence of cytomegalovirus (CMV) infection after
heart transplantation is similar to that in kidney or liver
transplantation, with estimates ranging from 9% to 35%,1
but the risk of progression to CMV disease is markedly
higher.1 One study observed a 25% risk of developing
biopsy-confirmed CMV disease during the first year post-
transplant in high-risk CMV-seronegative heart transplant
recipients.2 The highest rates of both CMV infection and
CMV disease—approximately 40%—are seen in lung and
heart-lung transplant patients.3 Treatment strategies aim to
avoid progression to organ involvement and development
of opportunistic infections and to reduce CMV-related com-
plications, such as graft rejection.
Intravenous (IV) ganciclovir and oral valganciclovir are
themainstay of treatment for CMVinfection or CMVdisease
after solid organ transplantation. In a population of mixed
solid organ transplant recipients, the VICTOR study showed
CMVviremia to be eradicated in approximately 70%of cases
by week 7 using either therapy.4 However, antiviral therapy
does not achieve viral clearance in all patients even when ex-
posure is confirmed to be adequate.5,6 Late-onset CMV dis-
ease, defined as occurring after cessation of prophylaxis, is
of particular concern. Studies have suggested the incidence
of late-onset CMV to be 29% and 49% in D+/R− recipientsReceived 15 July 2015. Revision received 13 November 2015.
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of heart7,8 and lung9 transplants, respectively, with an in-
creased risk if only a short course of antiviral prophylaxis is
given10,11 compared with extended antiviral prophylaxis.12
In cases of late-onset CMV infection, an antiviral treatment
course followed by secondary prophylaxis for one to three
months is recommended,13 and is usually adequate to con-
trol the infection. Other interventions may, however, become
necessary if invasive disease develops or ganciclovir resis-
tance emerges. In addition, prolonged therapy of ganciclovir
may lead to severe toxicity, of which bone marrow toxicity
with severe cytopenia is the most feared complication.14
There are circumstances where the use of CMV immuno-
globulin (CMVIG) may be an appropriate addition to ganci-
clovir and valganciclovir administration, although data are
currently highly limited.Of note, negativeCMV IgG serostatus
at the start of antiviral treatment in the VICTOR study of pa-
tients who had received various types of solid organ transplant
was associated with a significantly higher rate of recurrent dis-
ease compared with seropositive patients (27.6% vs 13.0%;
P=0.039), that is, an adequate anti-CMV IgG level is important
for mounting an effective anti-CMVresponse.4 Although the
main commercially available CMVIG preparations, Cytotect
or Cytogam, are licensed only for prophylactic use, some
centers use CMVIG off-label to support the treatment of
CMV infection or disease, for example, in patients with hypo-
gammaglobulinemia, in the event of ganciclovir resistance, or
in the event of tissue-invasive disease. This article considers
the available evidence concerning use of CMVIG to treat
CMV infection or CMV disease after thoracic transplanta-
tion (Tables 1 and 2).
TABLE 1.
Experience with CMVIG treatment for CMV infection or CMV disease in heart transplantation
First Author/Year N Case description CMVIG
Antiviral and
other treatment Outcome Comments
Schulz/2014 (personal
communication)15
15 Acute asymptomatic
CMV infection (PCR)
Cytotect single dose
(50 mL [2500 mg])
No antiviral therapy 9/15 (60%) negative
PCR after
1 treatment
1 patient had an
allergic reaction
5/15 (33%) negative
PCR after
2 treatments
1/5 (7%) required
more than
2 treatments
Rouphael et al/201116 1 59-year-old male with
asymptomatic
late-onset CMV
infection and CMV
prostatitis after
D+/R− tx
Single dose (details
not available)
Valganciclovir Undetectable CMV
PCR level
Prostate-specific
antigen (PSA)
decreased from
6.62 ng/mL to
0.32 ng/mL
Previously, the patient
had been treated with
IV ganciclovir for CMV
viremia, then with
valganciclovir + CMVIG,
after which CMV PCR
was negative
Reduction in
immunosuppression
(MMF discontinued,
doses of TAC and
steroids reduced)
Chou et al/199617 1 51-year-old man with
CMV retinitis 1 y after
heart tx
Cytotect, 200 mg/kg on
alternate days for
14 days with reduction
of immunosuppression
None Complete recovery of
visual acuity (from
20/200 to 20/20)
within 1 month with
healing of
retinal necrosis
No other complications
during 15-mo
follow-up
Cremer et al/198818 2 14-year-old
CMV-seronegative male
with clinical signs of
CMV infection (including
dyspnea) on day 59
CMVIG (type not
stated) 12.5 g/d
for 6 d
No antiviral therapy.
Reduction in
immunosuppression
(CsA dose reduction,
AZA withdrawn).
No antiviral therapy.
Reduction in
immunosuppression
(CsA dose reduction,
AZA withdrawn).
Amoxicillin 500 mg tid
Clinical improvement
by day 3 (positive
CMV detection to
day 142)
No relapse during
10 mo of
follow-up
29-year-old man (CMV
serostatus unknown)
with clinical signs of
infection (no pulmonary
involvement) on day 51
CMVIG (type not stated)
15 g/d for 5 d
Clinical improvement
by day 4 d (ongoing
CMV detection)
No relapse during
10 mo of
follow-up
AZA, azathioprine; CsA, cyclosporine; MMF, mycophenolate mofetil; TAC, tacrolimus; tid, 3 times a day; tx, transplantation
S6 Transplantation ■ March 2016 ■ Volume 100 ■ Number 3S www.transplantjournal.com
CMVIG in Uncomplicated Cases
Although antiviral agents remain the cornerstone for rou-
tine management of CMV infection or CMV disease, CMVIG
has been used as an alternative in asymptomatic cases. In a
series of 15 asymptomatic heart transplant recipients who
had acute CMVinfectionwith no CMVdisease and low viral
load (defined as 500-1000 CMVDNA copies/mL detected by
polymerase chain reaction [PCR]), Schulz et al15 administered
a single low dose of 50 mL Cytotect without antiviral therapy.
In 14 cases, viral clearancewas achieved. In 1 patient, a second
50-mL dose was given after the next PCR test continued to
show a viral load in the range of 500 to 1000 CMV DNA
copies/mL. Five patients subsequently relapsed, showing posi-
tive CMV viremia, and received another single 50-mL dose.
No antiviral therapy was given. Over half the patients (9/15,
60%) were found to be CMV-negative after just 1 dose, with
all but 1 clearing CMV infection with 2 doses. These encour-
aging results merit further investigation.
There are also published cases in which CMVIG has been
used to treat symptomatic CMV disease without concomi-
tant antiviral therapy.17,18 In an early report, Cremer et al18
described 2 heart transplant recipients who were not given
any antiviral therapy, and who presented with clinical symp-
toms consistent with CMV infection (Table 1). In the first case,
symptoms including dyspnea and pulmonary infection devel-
oped on day 59 posttransplant in a 14-year CMV-seronegative
boy. The CMVIG was started (12.5 g on 6 consecutive days),
and immunosuppression was reduced (cyclosporine concen-
tration was reduced from 600 ng/mL to 350 ng/mL and aza-
thioprine waswithdrawn). Symptoms improvedwithin 3 days.
The second case was a 29-year-old with CMV viremia who
presented with malaise, subfebrile raised temperature, epi-
gastric pain, and nausea but no pulmonary involvement. The
CMVIG was administered at a dose of 15 g for 5 consecutive
days, accompanied by cyclosporine reduction and azathioprine
discontinuation, leading to clinical improvement by day 4 and
hospital discharge by day 7. In both cases, there was no sign
of relapse after 10 months of follow-up.18 In another published
case report, a 51-year-oldmanwas found to have CMV-related
retinitis 1 year after heart transplantation.17 Antiviral therapy
was not instituted due to the clinician's concern about relapse
and the need for maintenance therapy. Instead, the patient
was successfully treated with CMVIG (Cytotect, 200 mg/kg
every other day for 2weeks) and reduced intensity of immuno-
suppression (Table 1).
López Garcia-Gallo et al20 have briefly described 4 cases
in which lung transplant recipients who developed invasive
CMV-related intestinal disease were treated with CMVIG
(200 mg/kg every 2 days for a week, weekly for a further
2 weeks, then once every 2weeks for amonth) in combination
with IV ganciclovir (Table 2). Two of the patients received a
D+/R− transplant, with gastritis and hepatitis diagnosed at
16 and 18 months posttransplant, respectively. All 4 cases
evolved favorably.
Intolerance to antiviral therapy can also represent a suit-
able occasion for introduction of CMVIG. Rouphael et al16
recently described the case of a 59-year-old male recipient
of a D+/R− heart transplant. Based on a preemptive manage-
ment protocol, a CMV level of 10 400 copies/mL on PCR at
week 6 posttransplant triggered treatment with IV ganciclo-
vir for 6weeks,which loweredCMV level to2900 copies/mL.
Oral valganciclovir was started. However, the patient devel-
oped neutropenia and valganciclovir had to be withdrawn
for 2 weeks. At this point, CMVIG was added once a month
for 6 months (the dose was not stated), and after 3 months,
the patient was CMV-negative.16
Recurrent CMV Infections
Despite high rates of response when CMV disease is treated
with IV ganciclovir or valganciclovir,6,22,23 recurrence remains
TABLE 2.
Experience with CMVIG treatment for CMV infection or CMV disease in lung and heart-lung transplantation
First Author/Year N Case description CMVIG
Antiviral and
other treatment Outcome Comments
Kneidinger
et al/201419
1 42-year-old female with
ganciclovir-resistant
CMV disease after
double D+/R− lung tx.
Severe side effects
with foscarnet
CMVIG (Cytotect)
100 IU (50 mg)/kg
Switch from ganciclovir
to forscarnet after
confirmation of
resistance (both
with CMVIG)
Viral load decreased
but forscarnet was
withdrawn due to side
effects, followed by
leflunomide and
reduction of
immunosuppression
At 5 mo post-tx,
CMV-specific T cells
were detected, with
CMV-specific antigens
After 1 year, patient
remains free of
CMV infection
López Garcia-Gallo
et al/200520
4 4 cases of invasive
CMV intestinal disease
after lung tx, including
2 D+/R− transplants
CMVIG (Cytotect)
200 mg/kg on
alternate days for
1 wk, weekly for
15 d, fortnightly for
1 mo (6 doses)
IV ganciclovir 5 mg/kg
for 21 d
Favorable outcome without
disease progression (no
further details provided)
Novick
et al/199021
1 Severe early fulminating
CMV pneumonitis
after intense
immunosuppression
due to recurrent
rejection in a heart-lung
tx recipient
CMVIG (Immuno-AG,
Vienna) 400 mg/kg
on days 1, 2, 7,
then 200 mg/kg on
day 14
IV ganciclovir (5 mg/kg
twice weekly): 1 course
of 6 wk, 1 course of
3 wk; finally
ongoing 5 mg/kg per
day 5 d per week
At last follow-up,
mildly restricted
pulmonary function
Complex course,
non-responsive to
ganciclovir alone but
clinical improvement
after addition of CMVIG
on two occasions
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a problem.24 Across all organ types, 1 study reported recurrent
CMV viremia or disease in 27% of patients within approxi-
mately 2.5 years after completion of a treatment course com-
prising IV ganciclovir and oral valganciclovir.25 Risk factors
for recurrent CMV infection include primary CMV infection
(ie, D+/R− recipients), CMV-IgG negative serostatus, high ini-
tial viral load, slow viral response to treatment, persistent vire-
mia during secondary prophylaxis, and antirejection therapy
during anti-CMV treatment.13,23
Isada et al26 described 13 cases of solid organ transplant
patients with ganciclovir-resistant CMV infection, pointing
out that 6 of the patients had received only oral ganciclovir
and 5 had received intermittent IV ganciclovir prophylaxis,
highlighting the need for therapeutic exposure levels. Con-
ventional short treatment courses are now being extended
at many centers in an attempt to avoid recurrence.27
Recurrent episodes of CMVdisease do not always respond
to additional antistatic treatment22 ormodification of the im-
munosuppression regimen, and the 2013 CMV Consensus
Conference of The Transplantation Society recommends that
in cases of recurrent CMV in thoracic transplant patients af-
ter a disease- and drug-free period, adjunctive CMVIG can be
considered in patients with hypogammaglobulinemia. Many
thoracic transplant patients receive mycophenolic acid im-
munosuppression, which inhibits T- and B-cell proliferation,
suppressing expression of adhesion molecules,28 and can in-
duce hypogammaglobulinemia. Novick et al21 have reported
a case in which a patient developed severe pulmonary rejec-
tion 3 weeks after receipt of a D+/R− heart-lung transplant,
requiring IV steroids and OKT3. The CMV pneumonitis
was detected, at which point the patient was leukopenic. In-
travenous ganciclovir did not lead to clinical or radiologic
improvement until after addition of CMVIG (400 mg/kg on
days 1, 2, and 7; 200 mg/kg on day 14). Four months later,
she developed shortness of breath, and CMV was detected
in the bronchoalveolar lavage fluid. Another 3-week course
of IV ganciclovir with concomitant CMVIG was initiated,
leading to resolution of symptoms, and she was subsequently
maintained on IV ganciclovir as an outpatient.
Ganciclovir-Resistant CMV Infection
Nonresponse to antiviral therapy may indicate the pres-
ence of viral resistance. Antiviral-resistant CMVismore com-
mon among thoracic organ recipients than other types of
solid organ transplantation,24 and often has an unfavorable
clinical outcome29,30 including tissue-invasive disease.13 The
incidence of resistance has been estimated to be between
0.25% and 5.3% after heart transplantation, and between
2.2% and 15.2% in lung transplant patients.24 Resistance
is more frequent in D+/R− recipients.30,31 One single-center
analysis of 274 heart transplant patients transplanted during
1995 to 2006 found a 1.5% incidence of ganciclovir-resistant
CMVdisease overall (5% amongD+/R− patients), which was
associated with prolonged CMV-related hospitalization.31 In
lung transplantation, full or partial resistance has been re-
ported in between 5%32 and 9%33 of patients and is associ-
ated with shorter survival and early onset of bronchiolitis
obliterans syndrome.32 Inadequate antiviral exposure can
lead to resistance,13 andmost cases have been reported in pa-
tients given oral ganciclovir rather than IV ganciclovir or
valganciclovir, suggesting that inadequate exposure may con-
tribute, although resistance to valganciclovir is not unknown.34
In 1 series of 5 lung transplant patients with CMV infection
who showed a persistent poor response to ganciclovir, ganci-
clovir levels were found to be subtherapeutic and genotyping
confirmed ganciclovir-resistant CMV.35 Longer exposure to
ganciclovir levels that does not completely inhibit CMV rep-
lication can lead to sudden appearance of resistance31,32,36,37
particularly in D+/R− recipients given intensive immuno-
suppressive regimens.38 There are few therapeutic options
for ganciclovir-resistant CMV infections. Foscarnet is the
most frequent choice, but is used off-label in this setting
and is limited by severe bone marrow and renal toxicity.
No other therapies are approved for ganciclovir-resistant
CMV infection.
There are no controlled studies comparing different
management strategies for ganciclovir-resistant CMV dis-
ease. Moreover, decision-making often has to be based on
clinical suspicion of resistance because of the time required
for laboratory confirmation. The most common mutation
(UL97) usually appears in isolation without cross-resistance
to the other antivirals licensed for CMV treatment, that
is, cidofovir or foscarnet. However, the combination of
UL97 and UL54 mutations usually confers cross-resistance
to cidofovir. Foscarnet is considered the antiviral agent of
choice in cases of ganciclovir-resistant CMV disease; how-
ever, even with the introduction of foscarnet, survival rates
can be low in thoracic transplant patients,26,30 and toxicity
is high.30 Other approaches include introduction of a non–
CMV-specific agent (leflunomide or artesunate) or switch
to mammalian target of rapamycin inhibition immunosup-
pression but these remain poorly documented.13
In cases of suspected ganciclovir-resistant CMV infection
where the patient is asymptomatic or not severely ill, in-
creased ganciclovir exposure with CMVIG and reduced im-
munosuppressive therapy have been proposed. Complete
discontinuation of immunosuppression is impracticable after
thoracic transplantation.
Hypogammaglobulinemia
To date, published results for treatment with CMVIG ther-
apy in patients with CMV infection and hypogammaglobu-
linemia are lacking. One center has reported the effect of
nonspecific IV immunoglobulin (Ig) treatment for severe in-
fections in heart transplant patients with hypogammaglo-
bulinemia (mean IgG 480 mg/dL).39 In the subpopulation
of 24 patients with CMV disease, 10 of whom received IV
Ig, the mortality rate was 20% compared with 71% in the
14 patients without IV Ig therapy (odds ratio, 0.06; 95%
confidence interval, 0.006-0.63; P = 0.01). Another report
has described outcomes in 5 heart transplant patients with
hypogammaglobulinemia, and recurrent CMV disease was
treated with IV infusions of pooled human IG (200-400 mg/g
per cycle) every 3 weeks until at least 3 months after a negative
assay for CMVantigenemia.40 Batches with the highest anti-
CMV titers were selected for use. Patients also received IV
ganciclovir. All patients became negative for CMVantigenemia,
at a mean of 34 days after the first infusion, and symptoms
resolved with no adverse events.
Reduction of antiproliferative immunosuppressive agents,
notably mycophenolic acid, is an alternative approach to re-
storing IgG levels in patients with hypogammaglobulinemia
and is an economical strategy. Use of IVIG, while not provid-
ing the same degree of anti-CMV antibody protection, may
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also be adequate in many cases and could offer a more cost-
effective approach to CMVIG although a benefit for IVIG in
the management of both CMVinfections and acute rejections
has not been confirmed.
Case Study
A 30-year-old woman received a high-urgency heart trans-
plant on March 19, 2010. Two years before referral to the
transplant center, she was diagnosed with dilated cardiomy-
opathy, probably caused by myocarditis, according to an
endomyocardial biopsy performed elsewhere. While awaiting
transplantation, her heart failure syndrome progressed rap-
idly, necessitating introduction of inotrope therapy followed
by insertion of an intra-aortic balloon pump and, finally, on
March 3, she received venoarterial extracorporeal membrane
oxygenation.
The donor, a 55-year-old woman, who died after cerebral
hemorrhage, was seropositive for CMV, whereas the recipi-
ent was CMV-negative.
The postoperative course was characterized by severe renal
impairment which required continuous veno-venous hemofil-
tration, and bymoderate right ventricle dysfunction secondary
to pretransplant reactive pulmonary hypertension.
Induction therapy comprised basiliximab (Simulect;Novartis
Pharma AG, Basel, Switzerland) administered on day 0 and
day 4, with maintenance therapy based on mycophenolate
mofetil (Cellcept; Roche Pharma AG, Basel, Switzerland)
and prednisone, started on day 2. Due to the severe renal im-
pairment, cyclosporine (Neoral; Novartis Pharma AG) was
started at a very low dose only on postoperative day 13 after
a second protocol endomyocardial biopsy showed grade 3A
cellular rejection. Graft rejection characterized the patient's
course. Shewas resistant to steroids and 3 consecutive biopsies
indicated grade 3A rejection despite intensive steroid therapy
and increasing cyclosporine exposure.
The patient received anti-CMV prophylaxis with valgan-
ciclovir 450mg every second day, based on her renal function.
Despite this, she developed a primary CMV infection during
valganciclovir treatment on April 19. CMVDNA PCR testing
of whole blood was positive, at 500 copies/mL, with the titer
rising to 6500 copies/mL on April 26. At that point, her mea-
sured creatinine clearance was only 10 mL/min so the val-
ganciclovir could not be increased. The patient was in very
poor condition, weighing only 40 kg with a BMI of 18 kg/m2.
In response to the primary CMV infection, she was switched
from valganciclovir to low-dose ganciclovir (1 mg/kg per
day) combined with CMVIg (Cytotect, Biotest AG, Dreieich,
Germany). The dose of CMVIg was an empirically defined
‘intensive’ regimen of 50 U/kg given every second day for a
total of four doses.
During a myocardial biopsy procedure the tricuspid valve
was damaged, causing severe tricuspid regurgitation followed
by refractory right heart failure. This ultimately required sur-
gery for tricuspid valve repair on April 29. During surgery an-
other biopsy samplewas taken and revealed ongoing grade 3A
rejection. However, the cellular infiltrate was very rich in
plasma cells, supporting the suspicion of concomitant parvo-
virus B19 infection which was later confirmed by myocar-
dial and blood PCR.
The patient received another course of steroids and CMVIg
(50U/kg) was continued twiceweekly fromMay 2 toMay 14.
TheCMVDNApeaked onMay 6 at 18 100 copies/mLduring
combined treatment with ganciclovir and CMVIg treatment,
then started to decline before becoming negative on June 17.
Ganciclovir was discontinued on June 21.
After the tricuspid valve repair, repeat biopsy was not fea-
sible. The presence of rejection was monitored by measuring
graft function with ultrasound and by screening for myocar-
dial edema (which is suggestive of possible rejection) using
cardiac magnetic resonance. These 2 noninvasive, albeit indi-
rect, monitoring techniques did not suggest significant myo-
cardial rejection relapse. Throughout the patient's course,
she remained negative for donor-specific antibodies.
The patient was discharged from the hospital on June 21.
This case reflects the complexity of managing heart trans-
plantation in an extremely ill and frail patient. Coexistence of
multiple comorbidities and procedural complications prevented
administration of adequate CMVprophylactic antiviral ther-
apy, further worsening the clinical situation. In this patient,
CMVIGwas used off-label as adjuvant therapy to treat a pri-
mary CMV infection, at a dosage significantly higher than
that typically recommended forCMVprophylaxis. Therewere
no adverse events associated with CMVIG treatment.
The breakthrough CMV infection during valganciclovir
prophylaxis may have been due to viral resistance, a possibil-
ity that was not investigated withmolecular testing. Based on
the clinical course, however, it was more likely caused by in-
adequate valganciclovir dosing necessitated by the presence
of severe renal dysfunction, coupled with a severely sup-
pressed immune system. In this context, the use of CMVIG
is likely to have made a substantial contribution to control-
ling CMV infection when added to ganciclovir therapy. No-
tably, the usual dose of ganciclovir when used to treat CMV
infection in patients with normal renal function is 2.5 mg/kg
twice per day, whereas here, the dose was 5 times lower. In ad-
dition, it could be speculated that due to the immunomodula-
tory properties of immunoglobulins, use of high-dose CMVIG
may have positively modulated the immune response, since no
further signs of rejection were detected despite a previous suc-
cession of steroid-resistant rejection episodes.
This case does not permit any conclusions about the
role of CMVIG beyond those specified on the product la-
bel. However, it raises important hypotheses about its
immunomodulatory properties and efficacy as adjuvant
therapy that merit further investigation in appropriately
designed prospective studies.
CONCLUSIONS
There is a pressing need for more rigorous comparative
data to define the optimal role for CMVIG therapy for
CMV treatment which balances the clinical benefit versus
the additional cost of therapy. Based on the current limited
evidence base, the use of CMVIG to treat CMV in adult or
pediatric thoracic transplant patients appears to be most ap-
propriate for ganciclovir-resistant infection or in serious or
complicated cases. The latter can potentially include (i) treat-
ment of severe clinicalmanifestations, such as pneumonitis or
eye complications; (ii) patients with a positive biopsy in end
organs, such as the lung or stomach; (iii) symptomatic cases
with rising PCR values (eg, higher than 5.0 log10) despite
antiviral treatment; (iv) CMV disease or CMV infection
with severe leukopenia (eg, arising from antiviral treat-
ment); (v) recurrent CMV infection or risk factors, such as
CMV-IgG negative serostatus; (vi) ganciclovir intolerance;
© 2016 Wolters Kluwer Schulz et al S9
(vii) or patients with hypogammaglobulinemia. There is no
consensus on the optimal CMVIG regimen when used as a
treatment for CMV infection or CMV disease, but dosages
are higher than for prophylactic use, with 200 to 400mg/kg
being typical.
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